Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 2
2008 2
2010 4
2011 1
2012 2
2013 7
2014 1
2015 4
2016 6
2017 2
2018 6
2019 5
2020 10
2021 9
2022 12
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Creelan BC, et al. Among authors: pilon thomas sa. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385708 Free PMC article. Clinical Trial.
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. Mohamed E, et al. Among authors: pilon thomas s. Immunity. 2020 Apr 14;52(4):668-682.e7. doi: 10.1016/j.immuni.2020.03.004. Immunity. 2020. PMID: 32294407 Free PMC article.
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Among authors: pilon thomas sa. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.
Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mulé JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Creasy CA, et al. Among authors: pilon thomas s. Clin Cancer Res. 2022 May 2;28(9):1911-1924. doi: 10.1158/1078-0432.CCR-21-1060. Clin Cancer Res. 2022. PMID: 35190823 Free PMC article.
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mulé JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Hall MS, et al. Among authors: pilon thomas s. Clin Cancer Res. 2022 Dec 15;28(24):5317-5329. doi: 10.1158/1078-0432.CCR-22-2103. Clin Cancer Res. 2022. PMID: 36215121 Free PMC article. Clinical Trial.
Immunotherapy on acid: opportunities and challenges.
Damgaci S, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ, Ibrahim-Hashim A. Damgaci S, et al. Among authors: pilon thomas s. Eur J Clin Nutr. 2020 Aug;74(Suppl 1):3-6. doi: 10.1038/s41430-020-0683-7. Eur J Clin Nutr. 2020. PMID: 32873950 Free PMC article. Review. No abstract available.
Current State of Cell Therapies for Genitourinary Malignancies.
Alkhouli MA, Bazargan S, Pilon-Thomas S, Poch M, Chahoud J. Alkhouli MA, et al. Among authors: pilon thomas s. Cancer J. 2022 Jul-Aug 01;28(4):294-300. doi: 10.1097/PPO.0000000000000604. Cancer J. 2022. PMID: 35880939 Review.
Immunotherapy for gastrointestinal malignancies.
Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Toomey PG, et al. Among authors: pilon thomas sa. Cancer Control. 2013 Jan;20(1):32-42. doi: 10.1177/107327481302000106. Cancer Control. 2013. PMID: 23302905 Free PMC article. Review.
79 results